Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects who are 11-55 years of age inclusive and who have given appropriate written assent and/or consent~Exclusion Criteria:~* Subjects with a previous or suspected disease caused by N. meningitidis~* previous immunization with a meningococcal vaccine or vaccine containing meningococcal antigen(s)~* previous or suspected disease caused by N. meningitidis~* Any serious acute, chronic or progressive disease~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Licensed Meningococcal Vaccine (Type: ACTIVE_COMPARATOR): Licensed meningococcal ACWY polysaccharide-protein conjugate vaccine
- Novartis MenACWY Conjugate Vaccine (Type: EXPERIMENTAL): Novartis meningococcal ACWY conjugate Vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).